Lutetium Lu 177 Dotatate (peptide conjugate)
Performance & EnduranceRadioactive peptide for neuroendocrine tumor treatment, targeted radionuclide therapy.
Key Benefits
- ✓Targeted radiation for NETs
- ✓Treats somatostatin receptor-positive tumors
- ✓Extends progression-free survival
- ✓Tumor-specific delivery
Dosing Information
Detailed Protocol
Administered via intravenous infusion in specialized nuclear medicine facilities. Given every 8 weeks for 4 doses. Requires extensive safety protocols. Medical use only.
About Lutetium Lu 177 Dotatate (peptide conjugate)
Lutetium Lu 177 dotatate (Lutathera) is a radiolabeled somatostatin analog that delivers targeted radiation to somatostatin receptor-positive neuroendocrine tumors. The peptide component targets tumors expressing somatostatin receptors.
Research Notes
FDA-approved in 2018 for gastroenteropancreatic NETs. NETTER-1 trial showed improved progression-free survival. Specialized treatment requiring nuclear medicine facilities.
Potential Side Effects
- •Nausea and vomiting
- •Myelosuppression
- •Liver toxicity
- •Kidney toxicity
- •Requires radiation safety measures
- •Hospitalization may be needed
Always consult with a healthcare professional before starting any peptide therapy.